Abstract
摘要
相似文献
1
Post-marketing surveillance.
Triangle. 1980;19(3-4):107-11.
2
Post-marketing surveillance of licensed medicinal and other products.
Health Bull (Edinb). 1981 Nov;39(6):356-66.
3
Present attitudes of governmental drug regulatory agencies.
Int J Clin Pharmacol. 1973 Apr;7(2):168-77.
4
Adverse drug reactions: definition of the problem.
Am J Epidemiol. 1971 Nov;94(5):403-4. doi: 10.1093/oxfordjournals.aje.a121335.
5
Drug hepatotoxicity from a regulatory perspective.
Clin Liver Dis. 2007 Aug;11(3):507-24, vi. doi: 10.1016/j.cld.2007.06.002.
6
[Intensified drug control--with drawbacks?].
Lakartidningen. 1983 Feb 16;80(7):575-81.
7
Post-marketing surveillance of adverse reactions to new medicines.
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
8
Discussion on control of new drugs.
Practitioner. 1971 Apr;206(234):546-50.
9
Monitoring of adverse reactions to drugs in the United Kingdom.
Proc R Soc Med. 1970 Dec;63(12):1302-4. doi: 10.1177/003591577006301234.
10
Side-effects of drugs. Monitoring adverse reactions.
Nurs Times. 1989;85(39):25-9.
Zotero 插件